JAGX - Jaguar Health Inc

0.491
-0.100   -20.265%

Share volume: 1,211,987
Last Updated: 03-09-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.20%

PREVIOUS CLOSE
CHG
CHG%
$0.59
-0.10
-0.17%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
53%
Profitability 50%
Dept financing 50%
Liquidity 21%
Performance 64%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-18.47%
1 Month
-23.52%
3 Months
-63.08%
6 Months
-76.28%
1 Year
-10.17%
2 Year
587.68%
Key data
Stock price
$0.49
P/E Ratio 
0.00
DAY RANGE
$0.48 - $0.60
EPS 
-$34.29
52 WEEK RANGE
$0.20 - $15.48
52 WEEK CHANGE
$3.04
MARKET CAP 
5.067 M
YIELD 
N/A
SHARES OUTSTANDING 
3.736 M
DIVIDEND
$0.00
EX-DIVIDEND DATE
03-24-2025
NEXT EARNINGS DATE
05-13-2025
BETA 
-0.29
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$748,895
AVERAGE 30 VOLUME 
$497,782
Company detail
CEO: Lisa A. Conte
Region: US
Website: jaguar.health
Employees: 50
IPO year: 2015
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Jaguar Health, Inc. focuses on developing prescription medicines for people and animals with gastrointestinal distress. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera.

Recent news